| 1 |
<p align="center"><b>RESEARCH AND DEVELOPMENT</b></p> |
<p align="center"><b>RESEARCH AND DEVELOPMENT</b></p> |
| 2 |
<p>PLIVA has a long and successful R&D track record that dates back to 1936. Its |
<p>PLIVA has a long and successful R&D track record that dates back to 1936. Its |
| 3 |
investments in R&D have grown to a decade high of USD 40 m and represent 10% |
investments in R&D have grown to a decade high of USD 40 m and represent 10% |
| 4 |
of PLIVA's healthcare turnover. This strategic goal for this continued investment |
of PLIVA's healthcare turnover. This strategic goal for this continued investment |
| 5 |
is to achieve a balanced portfolio for PLIVA's short, medium and long-term growth. |
is to achieve a balanced portfolio for PLIVA's short, medium and long-term growth. |
| 6 |
Commitment to a unique two-fold R&D strategy: discovery and development of novel |
Commitment to a unique two-fold R&D strategy: discovery and development of novel |
| 7 |
chemical entities and development of value added generics, is further supported |
chemical entities and development of value added generics, is further supported |
| 8 |
by PLIVA's licensing strategy.</p> |
by PLIVA's licensing strategy.</p> |
| 9 |
<p>PLIVA has focused its research expertise in two therapeutic areas: anti-infectives |
<p>PLIVA has focused its expertise on NCE research, and through this "Smart Discovery Strategy" globally |
| 10 |
and anti-inflammatories, and through this "Smart Discovery Strategy" globally |
competitive results are expected. Research activities are focussing on the early |
| 11 |
competitive results are expected. Research activities are focussing on the early |
phases of discovery and development only (i.e. Phase I/II clinical trials), |
| 12 |
phases of discovery and development only, while for advanced stages of development |
while for advanced stages of development |
| 13 |
and marketing, strategic partnerships will be established. PLIVA's vision in |
and marketing, strategic partnerships will be established. PLIVA's vision in |
| 14 |
research is to develop new drugs whose production will serve unmet medical needs |
research is to develop new drugs whose production will serve unmet medical needs |
| 15 |
and will have commercial returns in line with PLIVA's growth targets. At present, |
and will have commercial returns in line with PLIVA's growth targets.</p> |
| 16 |
there are three potential new drugs in PLIVA's pipeline.</p> |
<p align="center"><img src="p/Superrnd_ljudi_4.jpg" width="300" height="198" border=1></p> |
| 17 |
<p align="center"><img src="p/Superrnd_ljudi_4.jpg" width="300" height="198" border=1></p> |
<p>In development, superior results will be achieved by the in-house development |
| 18 |
<p>In development, superior results will be achieved by the in-house development |
of new molecules, the development of final pharmaceutical Rx or OTC drug forms, |
| 19 |
of new molecules, the development of final pharmaceutical Rx or OTC drug forms, |
and the development of Fine Chemicals processes. PLIVA's Competitive Generic |
| 20 |
and the development of Fine Chemicals processes. PLIVA's Competitive Generic |
Strategy is based on decades of experience and expertise in new API development |
| 21 |
Strategy is based on decades of experience and expertise in new API development |
coupled with regular and successful FDA inspections as well as PLIVA's excellence |
| 22 |
coupled with regular and successful FDA inspections as well as PLIVA's excellence |
in chemistry and the innovative improvement of existing drugs.</p> |
| 23 |
in chemistry and the innovative improvement of existing drugs.</p> |
<p>Our R&D strategy binds together a top quality international research team, |
| 24 |
<p>Our R&D strategy binds together a top quality international research team, |
a network of strategic partnerships with multinational and biotech companies |
| 25 |
a network of strategic partnerships with multinational and biotech companies |
and a broad cooperation with various international universities and institutes. |
| 26 |
and a broad cooperation with various international universities and institutes. |
These activities are further supported by an independent body that consists |
| 27 |
These activities are further supported by an independent body that consists |
of leading experts in the R&D areas of interest to PLIVA - PLIVA's International |
| 28 |
of leading experts in the R&D areas of interest to PLIVA - PLIVA's International |
Scientific Advisory Board.</p> |
|
Scientific Advisory Board.</p> |
|
|
<p>During the year 2000, 5 new patent applications were submitted in Croatia: |
|
|
TNF-a Inhibitors, New Coumarins, and Torasemide polymorphs; 6 new patent applications |
|
|
were submitted in the UK, resulting from the PLIVA-GlaxoWellcome joint macrolide |
|
|
project; 8 patents from the year 2000 and the previous year were also submitted |
|
|
abroad as PCTs: Macrolides and Torasemide polymorphs. As well, PLIVA researchers |
|
|
and scientists continue to publish and lecture in the professional media. </p> |
|
Parent Directory
| 
Revision Log
| 
Patch